Daktarin 2% w/w Cream
*Company:
KenvueStatus:
No Recent UpdateLegal Category:
Supply through pharmacy onlyActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 07 December 2020
File name
ie-mockup-leaflet-clean-2095.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - how to report a side effect
- Change to section 5 - how to store or dispose
- Change to section 6 - date of revision
Updated on 07 December 2020
File name
ie-spc-clean-2095.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Updated on 23 July 2020
File name
ie-mockup-leaflet-clean-2072.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 5 - how to store or dispose
- Change to section 6 - date of revision
Updated on 17 June 2019
File name
DKD02 1656 SPC V8.pdf
Reasons for updating
- File format updated to PDF
Legal category:Supply through pharmacy only
Updated on 25 January 2018
File name
PIL_9516_528.pdf
Reasons for updating
- New PIL for new product
Updated on 25 January 2018
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 23 January 2018
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Updated on 23 January 2018
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
|
PA Transfer from McNeil Healthcare (Ireland) Ltd to Johnson & Johnson (Ireland) Ltd. Change in PA number. Note the address and contact details remain the same. |
Updated on 19 January 2016
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.8
Angioedema moved from SOC "Immune System Disorders" to Skin and "subcutaneous Tissue Disorders"
Updated on 19 November 2015
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.3 - Addition of the underlined text:
Hypersensitivity to the active substance, other imidazole derivatives or to any of the excipients listed in section 6.1.Section 4.4 - addition of the following text
Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported during treatment with miconazole topical formulations. If a reaction suggesting hypersensitivity or irritation should occur, the treatment should be discontinued. Daktarin Cream must not come into contact with the mucosa of the eyes.
Section 4.8 - Additional of adverse event reporting details
(Miconazole PRAC updates, SNAS 1409)
Updated on 18 November 2015
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
Updated on 24 June 2014
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 16 October 2013
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 15 October 2013
Reasons for updating
- Change to dosage and administration
Updated on 18 April 2013
Reasons for updating
- Change due to user-testing of patient information
Updated on 19 October 2011
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.1 - List of excipients
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In Section 4.4, the following excipient warning has been added:
Benzoic acid (E210) can mildly irritate the skin, eyes and mucosal membranes.
Butylated hydroxyanisole (E320) may cause local skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucosa membranes.
In Section 6.1, the Macrogol content has been clarified:
Macrogol 6 (PEG 6)
Macrogol 32 (PEG 32)
Updated on 12 August 2010
Reasons for updating
- Change of manufacturer
Updated on 29 October 2009
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 23 October 2009
Reasons for updating
- Change to MA holder contact details
Updated on 13 May 2009
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to section 6.1 - List of excipients
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 9 - Date of renewal of authorisation
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
|
1. |
NAME OF THE MEDICINAL PRODUCT |
Changed to Daktarin 2% w/w Cream
|
|
2. |
QUALITATIVE AND QUANTITATIVE COMPOSITION |
Addition of : Excipients; contains 0.2% w/w benzoic acid (E210) and 0.005% w/w butylated hydroxyanisole (E320)
Addition of Full statement added: For a full list excipients, see section 6.1. |
|
6.1 |
List of excipients |
Name change: unsaturated polyglycolysed glycerides to oleoylmacroglycerides |
|
9. |
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION |
Renewal of product licence 31 March 2008 |
|
10. |
DATE OF REVISION OF THE TEXT |
Changed to May 2009
|
Updated on 11 May 2009
Reasons for updating
- Change of trade or active ingredient name
- Change to date of revision
Updated on 19 January 2009
Reasons for updating
- Change to side-effects
- Change to drug interactions
- Change to date of revision
Updated on 19 January 2009
Reasons for updating
- PIL re-instated
Updated on 20 March 2006
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Updated on 20 March 2006
Reasons for updating
- Change to drug interactions
- Change to side-effects
Updated on 17 May 2005
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
- Change to section 9 - Date of renewal of authorisation
Legal category:Supply through pharmacy only
Updated on 31 March 2005
Reasons for updating
- New PIL for medicines.ie
Updated on 05 June 2003
Reasons for updating
- New SPC for medicines.ie
Legal category:Supply through pharmacy only